Novel clinical trial designs for the development of new antiretroviral agents

about

The future of HIV treatment.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

P2860

Q36115687-7A5DB076-F01F-4289-852E-4368ED68FF44 Q39433833-0E08DF17-F405-4145-BA5A-310B0CC34A25

P2860

Novel clinical trial designs for the development of new antiretroviral agents

Item

http://www.wikidata.org/entity/Q35931303

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Novel clinical trial designs for the development of new antiretroviral agents

@ast

Novel clinical trial designs for the development of new antiretroviral agents

@en

type

Item

label

Novel clinical trial designs for the development of new antiretroviral agents

@ast

Novel clinical trial designs for the development of new antiretroviral agents

@en

prefLabel

Novel clinical trial designs for the development of new antiretroviral agents

@ast

Novel clinical trial designs for the development of new antiretroviral agents

@en

P1476

Novel clinical trial designs for the development of new antiretroviral agents

@en

P2093

Filip Josephson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Murray

http://www.w3.org/2001/XMLSchema#string

Jur Strobos

http://www.w3.org/2001/XMLSchema#string

Kimberly Struble

http://www.w3.org/2001/XMLSchema#string

Nina Mani

http://www.w3.org/2001/XMLSchema#string

Peter Miele

http://www.w3.org/2001/XMLSchema#string

Roy M Gulick

http://www.w3.org/2001/XMLSchema#string

Veronica Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Raltegravir with optimized background therapy for resistant HIV-1 infection

CD4+ count-guided interruption of antiretroviral treatment

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs.

The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Maraviroc for previously treated patients with R5 HIV-1 infection

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

P304

899-907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E3283519371

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221802245

http://www.w3.org/2001/XMLSchema#string

P698

22301412

http://www.w3.org/2001/XMLSchema#string

P932

3343181

http://www.w3.org/2001/XMLSchema#string

Novel clinical trial designs for the development of new antiretroviral agents

about

P2860

P2860

Novel clinical trial designs for the development of new antiretroviral agents

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932